GLP-1 drugs may slow aging, raising questions about Canadian access and coverage

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Scientists studying biological markers of aging reported in October 2026 that GLP-1 receptor agonists, a drug class that includes semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for chronic weight management) and tirzepatide (sold in Canada as Mounjaro), appear to influence molecular processes tied to how quickly the body ages at a cellular level, according to reporting by CNN carried by CTV News. The findings are preliminary and come from studies examining epigenetic clocks and inflammatory biomarkers, not from randomized trials designed to test longevity as a primary outcome. For Canadians already on these drugs for approved indications, or for those wondering whether to seek them out, the practical answer right now is the same: Health Canada has not approved any GLP-1 drug as an anti-aging therapy, and no provincial drug plan covers them on that basis.

What changed

GLP-1 is short for glucagon-like peptide-1, a hormone the gut releases after eating. GLP-1 receptor agonists mimic that hormone, slowing gastric emptying, reducing appetite, and prompting the pancreas to release insulin in response to meals. They were developed for type 2 diabetes and later studied for obesity. The anti-aging angle is newer.

Researchers have been applying epigenetic clocks, computational tools that estimate biological age from patterns of DNA methylation, to blood samples from people taking GLP-1 drugs. Several analyses have found that patients on semaglutide show biological age readings somewhat younger than their chronological age would predict, and that inflammatory markers associated with accelerated aging, including C-reactive protein and interleukin-6, drop alongside weight and blood sugar. A 2024 study published in Nature Aging examining data from the SUSTAIN and STEP clinical trial programs found reductions in multiple aging biomarkers in participants taking semaglutide compared with placebo, though the authors were careful to note that biomarker changes do not automatically translate into longer or healthier lives.

The hypothesis gaining traction is that the drugs' effects on visceral fat, systemic inflammation, and metabolic function collectively reduce what geroscientists call the "biological aging rate." Visceral fat is a known driver of chronic low-grade inflammation, and chronic inflammation is one of the better-documented contributors to age-related disease. Reducing it through any means, including weight loss, tends to move aging biomarkers in a favorable direction. Whether GLP-1 drugs do something beyond what weight loss alone would achieve is still an open question.

What this means in Canada

Health Canada has approved semaglutide under two separate notices of compliance: Ozempic (0.5 mg, 1 mg, 2 mg weekly injection) for type 2 diabetes, and Wegovy (2.4 mg weekly injection) for chronic weight management in adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related comorbidity. Tirzepatide (Mounjaro) holds a Health Canada approval for type 2 diabetes. None of these approvals extend to longevity or anti-aging indications, and Health Canada has not issued any guidance suggesting it is reviewing such an application.

Provincial pharmacare coverage is uneven and restrictive. In Ontario, OHIP's Exceptional Access Program covers Ozempic for type 2 diabetes patients who meet specific glycemic criteria; Wegovy is not covered under the Ontario Drug Benefit formulary as of October 2026. In Quebec, the Régie de l'assurance maladie du Québec (RAMQ) covers semaglutide for diabetes but not for obesity alone. British Columbia's PharmaCare and Alberta's Alberta Health Care Insurance Plan (AHCIP) drug benefit programs follow similar patterns: diabetes indication covered with conditions, obesity indication generally not covered or covered only under limited special authority. Prince Edward Island and several other provinces have added obesity coverage under specific criteria, but the picture varies month to month as formularies are updated.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a position statement on GLP-1 drugs and aging. The Canadian Diabetes Association (now Diabetes Canada) has published prescribing guidance for semaglutide in type 2 diabetes, but that guidance does not address longevity use. No Canadian clinical society has done so.

For Canadians paying out of pocket, Wegovy runs approximately CAD $400 to $500 per month depending on pharmacy and province. Ozempic at diabetes doses is cheaper but still CAD $200 to $300 monthly without coverage. Supply shortages have affected both products intermittently since 2023, and Health Canada has periodically updated its shortage notices.

Canadian telehealth platforms including Felix (a Canadian men's and primary care platform), Cleo (a Canadian women's health platform), and Science & Humans (scienceandhumans.com), which focuses on hormone and metabolic health, have begun offering GLP-1 prescribing consultations for eligible patients. Maple and Telus Health also connect patients with physicians who can prescribe within approved indications. None of these platforms can legally prescribe for an unapproved anti-aging indication, and none currently claim to do so. US-only platforms such as Hone Health and Midi do not serve Canadian patients.

What Canadian patients should know

If you have type 2 diabetes or obesity and your physician has already discussed a GLP-1 drug with you, the emerging aging data is interesting context but should not change the conversation much. The drugs are prescribed for established indications with well-characterized benefit-risk profiles. The potential effect on biological aging is a secondary observation from trials designed for other purposes.

If you are metabolically healthy and interested in these drugs purely for longevity, there is no approved pathway in Canada for that use. A physician who prescribes a GLP-1 drug off-label for anti-aging purposes would be doing so outside any Health Canada-approved indication, without clinical society support, and in a context where the long-term safety data for people without diabetes or obesity is thin. The side effect profile, which includes nausea, vomiting, gastroparesis risk, and rare but serious pancreatitis, is the same regardless of why the drug is prescribed.

Provincial coverage will not apply to off-label longevity use. Patients would pay full cost out of pocket, and private insurers are unlikely to cover a non-approved indication.

If you are on a GLP-1 drug for an approved indication and want to understand what the aging research might mean for you personally, that is a reasonable question to bring to your prescribing physician or endocrinologist.

Limitations and open questions

The anti-aging findings rest almost entirely on biomarker data, not on clinical outcomes like lifespan or rates of age-related disease. Epigenetic clocks are research tools; they are not validated diagnostic instruments, and a favorable clock reading does not guarantee any particular health outcome. The studies conducted so far were not designed to test longevity as a primary endpoint, so the effect sizes and their clinical meaning are genuinely uncertain.

It is also unclear whether the biological age changes observed are driven by the GLP-1 mechanism itself or simply by weight loss and inflammation reduction, effects achievable through other means. Separating drug-specific effects from weight-loss effects requires trials that control for weight change, and those trials have not been completed.

Health Canada has not signaled any intention to review a longevity indication for any GLP-1 drug. The Canadian Institutes of Health Research (CIHR) has funded metabolic research involving GLP-1 drugs, but no large Canadian longevity trial is currently registered. The SOGC has not commented. Until randomized trial data with hard clinical endpoints exists, and until a regulatory submission is made and reviewed, the anti-aging framing remains a hypothesis worth watching, not a clinical recommendation.

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.